These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3323092)

  • 21. Receptor-isoform-selective insulin analogues give tissue-preferential effects.
    Vienberg SG; Bouman SD; Sørensen H; Stidsen CE; Kjeldsen T; Glendorf T; Sørensen AR; Olsen GS; Andersen B; Nishimura E
    Biochem J; 2011 Dec; 440(3):301-8. PubMed ID: 21851336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence concerning the mechanism of insulin-receptor interaction and the structure of the insulin receptor from biological properties of covalently linked insulin dimers.
    Tatnell MA; Jones RH; Willey KP; Schüttler A; Brandenburg D
    Biochem J; 1983 Dec; 216(3):687-94. PubMed ID: 6365079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in organizational structure of insulin receptor on rat adipocyte and liver plasma membranes: role of disulfide bonds.
    Schweitzer JB; Smith RM; Jarett L
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4692-6. PubMed ID: 7001464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin. Studies in cultured IM-9 lymphocytes and in vivo and in vitro in rats.
    Peavy DE; Brunner MR; Duckworth WC; Hooker CS; Frank BH
    J Biol Chem; 1985 Nov; 260(26):13989-94. PubMed ID: 4055768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of placement of tryptophan residues in selected A-chain positions on the biological profile of insulin.
    Chu YC; Burke GT; Ross JB; Katsoyannis PG
    J Protein Chem; 1993 Aug; 12(4):499-505. PubMed ID: 8251071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo potency of insulin analogues designed for clinical use.
    Vølund A; Brange J; Drejer K; Jensen I; Markussen J; Ribel U; Sørensen AR; Schlichtkrull J
    Diabet Med; 1991 Nov; 8(9):839-47. PubMed ID: 1663018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of insulin to bovine liver plasma membrane. Use of insulin analogues modified at the A1 residue.
    Rösen P; Simon M; Reinauer H
    Biochem J; 1980 Mar; 186(3):945-52. PubMed ID: 6994716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin analogues with modifications at position B26. Divergence of binding affinity and biological activity.
    Záková L; Kazdová L; Hanclová I; Protivínská E; Sanda M; Budesínský M; Jirácek J
    Biochemistry; 2008 May; 47(21):5858-68. PubMed ID: 18452310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A superactive insulin: [B10-aspartic acid]insulin(human).
    Schwartz GP; Burke GT; Katsoyannis PG
    Proc Natl Acad Sci U S A; 1987 Sep; 84(18):6408-11. PubMed ID: 3306677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and biological properties of [LeuB24, LeuB25]human insulin.
    Jonczyk A; Keefer LM; Naithani VK; Gattner HG; De Meyts P; Zahn H
    Hoppe Seylers Z Physiol Chem; 1981 May; 362(5):557-61. PubMed ID: 7019034
    [No Abstract]   [Full Text] [Related]  

  • 31. Sphingosine, an inhibitor of protein kinase C, suppresses the insulin-like effects of growth hormone in rat adipocytes.
    Smal J; De Meyts P
    Proc Natl Acad Sci U S A; 1989 Jun; 86(12):4705-9. PubMed ID: 2660145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perturbation of insulin-receptor interactions by intramolecular hormone cross-linking. Analysis of relative movement among residues A1, B1, and B29.
    Nakagawa SH; Tager HS
    J Biol Chem; 1989 Jan; 264(1):272-9. PubMed ID: 2642474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [12-asparagine-B] human insulin. An analogue with modification in the hydrophobic core of insulin.
    Schwartz GP; Burke GT; Katsoyannis PG
    Int J Pept Protein Res; 1981 Feb; 17(2):243-55. PubMed ID: 7014485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-standard insulin design: structure-activity relationships at the periphery of the insulin receptor.
    Weiss MA; Wan Z; Zhao M; Chu YC; Nakagawa SH; Burke GT; Jia W; Hellmich R; Katsoyannis PG
    J Mol Biol; 2002 Jan; 315(2):103-11. PubMed ID: 11779231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A shortened insulin with full in vitro potency.
    Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
    Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of insulin fragments on biological activity of insulin and desoctapeptide insulin. II. Enhanced binding and mechanism studies.
    Kikuchi K; Larner J; Freer RJ; Day AR
    J Biol Chem; 1981 Sep; 256(18):9445-9. PubMed ID: 7026554
    [No Abstract]   [Full Text] [Related]  

  • 37. [LeuB24]- and [LeuB25]insulins are not antagonists of lipogenesis in adipocytes.
    Diaconescu C; Saunders D; Gattner HG; Brandenburg D
    Hoppe Seylers Z Physiol Chem; 1982 Feb; 363(2):187-92. PubMed ID: 7037593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potency of biosynthetic human insulin determined in vitro.
    Fussgaenger RD; Ditschuneit HH; Martini H; Wiebauer-De Lenardis H; Etzrodt H; Thun C; Ditschuneit H; Pfeiffer EF; Enzmann F
    Diabetes Care; 1981; 4(2):228-34. PubMed ID: 7011733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro bioactivity of insulin analogues: lipogenic and anti-lipolytic potency and their interaction with the effect of native insulin.
    Ellis MJ; Darby SC; Jones RH; Sönksen PH
    Diabetologia; 1978 Nov; 15(5):403-10. PubMed ID: 738550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions.
    Nakagawa SH; Tager HS
    Biochemistry; 1992 Mar; 31(12):3204-14. PubMed ID: 1554705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.